ESC 365 - Effects of CYP3A4*22 carrier and CYP3A5 expressor status on clinical outcome in patients treated with ticagrelor for acute coronary syndrome

ESC Professional Premium Access

Effects of CYP3A4*22 carrier and CYP3A5 expressor status on clinical outcome in patients treated with ticagrelor for acute coronary syndrome

Session: Coronary artery disease - Pharmacotherapy 2

Topic: Pharmacotherapy

Speaker: Doctor J. Azzahhafi (Nieuwegein, NL)

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Doctor Jaouad Azzahhafi

St Antonius Hospital, Nieuwegein (Netherlands (The))

0 follower

4 more presentations in this session

P2Y12 inhibitors monotherapy in patients undergoing complex vs. non-complex percutaneous coronary intervention: a meta-analysis of randomized trials

Speaker: Doctor A. Oliva (New York, US)

Liposomal docosahexaenoic acid halts atherosclerosis progression

Speaker: Miss S. Chong (Singapore, SG)

The effect of vitamin k2 supplementation on coronary artery disease in a randomized multicenter trial

Speaker: Doctor S. Hasific (Odense, DK)

Comparison of the Efficacy and Safety between different Oral P2Y12 Receptor Inhibitors in Patients with Acute Coronary Syndrome: a Systematic Review and Meta-Analysis

Speaker: Doctor A. Lepone (Pisa, IT)

Access the full session

Coronary artery disease - Pharmacotherapy 2

Speakers: Doctor J. Azzahhafi, Doctor A. Oliva, Miss S. Chong, Doctor S. Hasific, Doctor A. Lepone

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources